Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eururo.2020.12.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Spatial Transcriptomic Profiling to Characterize the Nature of Peripheral- Versus Transition-zone Prostate Cancer.
Eur Urol Focus
November 2024
Department of Urology, Michigan Medicine, Ann Arbor, MI, USA; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; Michigan Center for Translational Pathology, Michigan Medicine, Ann Arbor, MI, USA. Electronic address:
Background And Objective: Prostate cancer (PC) in the transition zone (TZ) has better prognosis than peripheral-zone (PZ) PC despite higher prostate-specific antigen (PSA) in patients with TZ tumors. Our aim was to characterize molecular differences between TZ and PZ tumors and their clinical implications.
Methods: We performed spatial whole-transcriptome analyses of 50 regions of interest (ROIs) from three patients with PZ and/or TZ PC.
Detection of Germline Variants in Patients With Localized and Metastatic Prostate Cancer Through Guideline-Based Testing.
Urol Pract
January 2025
Department of Urology, University of Michigan, Ann Arbor, Michigan.
Article Synopsis
- There is growing recognition that prostate cancer patients often have germline variants that can have significant implications for their health and that of their families, necessitating a deeper understanding of which individuals may carry these variants.
- A study involving 505 prostate cancer patients was conducted, tracking various factors and evaluating the presence of pathogenic or likely pathogenic (P/LP) germline variants through genetic testing aligned with NCCN guidelines.
- The study found that the occurrence of P/LP variants was similar across different age groups and clinical characteristics, with only the age at testing in metastatic patients showing a predictive association for these variants, indicating challenges in refining existing clinical guidelines.
Differences in mutations across tumour sizes in clear-cell renal cell carcinoma.
BJU Int
September 2024
Department of Urologic Surgery, UC Davis, Sacramento, CA, USA.
Objective: To assess the distribution of key mutations across tumour sizes in clear-cell renal cell carcinoma (ccRCC), and secondarily to examine the prognostic impact of aggressive mutations in smaller ccRCCs.
Patient And Methods: The distribution of mutations (VHL, PBRM1, SETD2, BAP1 and CDKN2A loss) across tumour sizes was assessed in 1039 ccRCCs treated with nephrectomy in cohorts obtained from the Tracking Cancer Evolution (TRACERx), The Cancer Genome Atlas (TCGA) and the Cancer Genomics of the Kidney (CAGEKID) projects. Logistic regression was used to model the presence of each mutation against size.
Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response.
Eur Urol
November 2024
Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA; Department of Pathology, University of Michigan, Ann Arbor, MI, USA. Electronic address:
Article Synopsis
- The study focuses on creating patient-derived organoid (PDO) models from muscle-invasive bladder cancer tumors to better predict therapy responses and improve treatment outcomes.
- Researchers collected tumor samples from bladder cancer patients to develop these PDOs and tested them against various drugs in a lab setting, using advanced molecular profiling techniques to assess their characteristics.
- The findings showed that short-term PDOs accurately reflect the original tumors and identified potential biomarkers associated with drug responses, particularly for gemcitabine, but further validation of these results is necessary.
A systematic review of family history, race/ethnicity, and genetic risk on prostate cancer detection and outcomes: Considerations in PSA-based screening.
Urol Oncol
January 2025
Department of Urology, University of Michigan, Ann Arbor, MI. Electronic address:
Aim: To investigate the role of family history, race/ethnicity, and genetics in prostate cancer (PCa) screening.
Methods: We conducted a systematic review of articles from January 2013 through September 2023 that focused on the association of race/ethnicity and genetic factors on PCa detection. Of 10,815 studies, we identified 43 that fulfilled our pre-determined PICO (Patient, Intervention, Comparison and Outcome) criteria.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!